Latest news with #HengruiPharma
Yahoo
3 days ago
- Business
- Yahoo
Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation
SHANGHAI, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3 (local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global experts. In the field of breast cancer, results from 19 studies evaluating the company's innovative drugs—pyrotinib, dalpiciclib, camrelizumab, apatinib, adebrelimab, Trastuzumab rezetecan (SHR-A1811), and SHR-2017, either in combination with each other or with chemotherapies, were presented at ASCO 2025. Notably, 7 studies involving pyrotinib and 6 studies involving dalpiciclib were selected, with both agents consistently demonstrating promising efficacy, reinforcing their established roles in breast cancer treatment. Furthermore, studies evaluating SHR-A1811 and adebrelimab were selected for rapid oral presentations, attracting considerable attention from the industry. In the field of gastrointestinal cancers, drugs such as camrelizumab, apatinib, adebrelimab, and SHR-8068 were featured in a total of 30 accepted studies. Notably, camrelizumab was included in 21 of these studies, demonstrating its broad therapeutic profile and potential while reinforcing its position as a key focus at ASCO. This further solidifies the achievements of China-developed PD-1 inhibitors on the global stage. Additionally, adebrelimab, which has achieved significant breakthroughs in lung cancer in recent years, is actively expanding into new indications. At this year's ASCO, five related studies exploring adebrelimab's efficacy in indications such as hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) , and pancreatic cancer were presented. The ongoing emergence of cutting-edge research on both established and emerging agents holds promise for improving clinical outcomes for patients with gastrointestinal tumors. Across a wide range of disease areas—including lung cancer, gynecologic cancers, lymphoma, bladder cancer, head and neck cancer, melanoma, sarcoma, nasopharyngeal carcinoma, chordoma, salivary gland cancer, thymic cancer, desmoid tumors, and salivary duct carcinoma—Hengrui Pharma's innovative oncology portfolio (camrelizumab, apatinib, adebrelimab, pyrotinib, dalpiciclib, fluzoparib, famitinib, SHR-A1811, SHR-1501, SHR-1701, SHR-1826, SHR-A1912, and SHR-A2102) was featured in 22 research presentations at ASCO 2025. These comprised 4 oral presentations, 2 rapid oral presentations, 12 poster presentations, and 4 online publications, collectively demonstrating the company's robust R&D capabilities. Additionally, one online publication highlighted ondansetron oral soluble film, underscoring its favorable efficacy in preventing and treating chemotherapy-induced nausea and vomiting (CINV). For 15 consecutive years, Hengrui Pharma has consistently presented its cutting-edge research at the ASCO Annual Meeting, highlighting the company's global leadership in oncology drug research and development while showcasing China's robust pharmaceutical innovation capabilities to the international academic community. The inclusion of 70 Hengrui-sponsored studies at this year's meeting reflects the strong foundation laid by the company's portfolio of 23 marketed innovative drugs and a robust pipeline of over 90 candidates currently in development. Looking ahead, Hengrui will remain committed to its patient-centric approach, striving to develop advanced therapeutics that support the "Healthy China" initiative and enhance clinical outcomes for patients globally. View original content: SOURCE Hengrui Pharma Sign in to access your portfolio
RTÉ News
24-04-2025
- Business
- RTÉ News
Merck posts higher profit, puts tariffs cost at $200m
Merck said today its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a January decision to pause shipments of its Gardasil vaccine to China due to a downturn in demand. For the full year, Merck lowered its earnings outlook slightly, citing an estimated $200m in additional costs for tariffs implemented to date and a charge related to a licensing deal with Hengrui Pharma. The drugmaker said it earned $5.61 billion in the first quarter, or $2.22 a share, excluding one-time items. Analysts had expected a profit of $2.14 a share, according to LSEG data. Worldwide sales dipped 2% to $15.5 billion, exceeding the average analyst forecast of $15.3 billion. Excluding the impact of foreign exchange rates, sales rose 1%, Merck said. Net earnings rose 7% to $2.01 per share. Sales of Gardasil, a vaccine that prevents cancers caused by the human papillomavirus, fell 41% to $1.3 billion, which was in line with analyst expectations. Sales of cancer immunotherapy Keytruda rose 4% to $7.2 billion, short of analyst estimates of $7.4 billion. For the lung disease drug Winrevair launched last year, sales totaled $280m. Animal health sales grew 5% to $1.6 billion. For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share forecast to between $8.82 and $8.97, from a previous $8.88 to $9.03. Analysts have forecast 2025 earnings of $8.95 per share on revenue of $65 billion. Merck said the outlook includes the $200m impact of tariffs implemented to date by the US government on imports from other countries, plus the cost of tariffs imposed by foreign governments on the United States, particularly those related to China. The Trump Administration recently opened a national security investigation into pharmaceuticals aimed at showing why the US needs tariffs to boost domestic manufacturing of medicines.
Reuters
24-04-2025
- Business
- Reuters
Merck posts higher profit, puts tariffs cost at $200 million
Summary Companies Q1 earnings per share at $2.22 vs forecast at $2.14 a share World sales dip 2% to $15.5 billion vs forecast $15.3 billion Sales of Gardasil fall 41% to $1.3 billion April 24 (Reuters) - Merck (MRK.N), opens new tab on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a January decision to pause shipments of its Gardasil vaccine to China due to a downturn in demand. For the full year, Merck lowered its earnings outlook slightly, citing an estimated $200 million in additional costs for tariffs implemented to date and a charge related to a licensing deal with Hengrui Pharma ( opens new tab. here. The drugmaker said it earned $5.61 billion in the first quarter, or $2.22 a share, excluding one-time items. Analysts had expected a profit of $2.14 a share, according to LSEG data. Worldwide sales dipped 2% to $15.5 billion, exceeding the average analyst forecast of $15.3 billion. Excluding the impact of foreign exchange rates, sales rose 1%, Merck said. Net earnings rose 7% to $2.01 per share. Sales of Gardasil, a vaccine that prevents cancers caused by the human papillomavirus, fell 41% to $1.3 billion, which was in line with analyst expectations. Sales of cancer immunotherapy Keytruda rose 4% to $7.2 billion, short of analyst estimates of $7.4 billion. For the lung disease drug Winrevair launched last year, sales totaled $280 million. Animal health sales grew 5% to $1.6 billion. For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share forecast to between $8.82 and $8.97, from a previous $8.88 to $9.03. Analysts have forecast 2025 earnings of $8.95 per share on revenue of $65 billion. Merck said the outlook includes the $200 million impact of tariffs implemented to date by the U.S. government on imports from other countries, plus the cost of tariffs imposed by foreign governments on the United States, particularly those related to China. The Trump Administration recently opened a national security investigation into pharmaceuticals aimed at showing why the U.S. needs tariffs to boost domestic manufacturing of medicines.
Yahoo
24-04-2025
- Business
- Yahoo
Merck posts higher profit, puts tariffs cost at $200 million
By Deena Beasley (Reuters) -Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a January decision to pause shipments of its Gardasil vaccine to China due to a downturn in demand. For the full year, Merck lowered its earnings outlook slightly, citing an estimated $200 million in additional costs for tariffs implemented to date and a charge related to a licensing deal with Hengrui Pharma. The drugmaker said it earned $5.61 billion in the first quarter, or $2.22 a share, excluding one-time items. Analysts had expected a profit of $2.14 a share, according to LSEG data. Worldwide sales dipped 2% to $15.5 billion, exceeding the average analyst forecast of $15.3 billion. Excluding the impact of foreign exchange rates, sales rose 1%, Merck said. Net earnings rose 7% to $2.01 per share. Sales of Gardasil, a vaccine that prevents cancers caused by the human papillomavirus, fell 41% to $1.3 billion, which was in line with analyst expectations. Sales of cancer immunotherapy Keytruda rose 4% to $7.2 billion, short of analyst estimates of $7.4 billion. For the lung disease drug Winrevair launched last year, sales totaled $280 million. Animal health sales grew 5% to $1.6 billion. For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share forecast to between $8.82 and $8.97, from a previous $8.88 to $9.03. Analysts have forecast 2025 earnings of $8.95 per share on revenue of $65 billion. Merck said the outlook includes the $200 million impact of tariffs implemented to date by the U.S. government on imports from other countries, plus the cost of tariffs imposed by foreign governments on the United States, particularly those related to China. The Trump Administration recently opened a national security investigation into pharmaceuticals aimed at showing why the U.S. needs tariffs to boost domestic manufacturing of medicines. (Reporting By Deena Beasley; Editing by Tom Hogue) Sign in to access your portfolio
CNBC
24-04-2025
- Business
- CNBC
Merck lowers profit outlook, partly due to $200 million expected tariff hit
Merck on Thursday lowered its full-year profit guidance, citing $200 million in estimated costs for tariffs and a charge tied to a recent deal. The company now expects its 2025 adjusted earnings to come in between $8.82 and $8.97, down slightly from a previous outlook of 8.88 to $9.03 per share. The company said the expected tariff charge primarily reflects levies between the U.S. and China, and Canada and Mexico to a lesser degree. Merck has built a robust presence in China, which is considered one of the company's most important markets and is home to some of its partners and manufacturing and research and development sites. Merck noted that the new outlook does not account for President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S., which is prompting some drugmakers to bolster their U.S. manufacturing footprints. That includes Merck, which has invested $12 billion in U.S. manufacturing and research and development and expects to put more than $9 billion more into the country by the end of 2028. But the guidance does include a one-time charge of roughly 6 cents per share related to the company's license agreement with Hengrui Pharma, which it announced in March. Merck reiterated its full-year sales forecast of between $64.1 billion and $65.6 billion. Also on Thursday, the drugmaker reported first-quarter revenue and profit that beat expectations, as it said it saw strength in its oncology portfolio and animal health products. Merck also cited "increasingly meaningful" sales contributions from two recently launched drugs. They are Winrevair, which is used to treat a rare, deadly lung condition, and Capvaxive, a vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and lung infection. Sales of those drugs will likely be critical to Merck's efforts to offset losses from its top-selling cancer therapy Keytruda, which will lose exclusivity in 2028. Here's what Merck reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: The company posted net income of $5.08 billion, or $2.01 per share, for the quarter. That compares with a net income of $4.76 billion, or $1.87 per share, during the year-earlier period. Excluding acquisition and restructuring costs, Merck earned $2.22 per share for the first quarter. Merck raked in $15.53 billion in revenue for the quarter, down 2% from the same period a year ago. Merck's pharmaceutical unit, which develops a wide range of drugs, booked $13.64 billion in revenue during the first quarter. That's down 3% from the same period a year ago. Keytruda recorded $7.21 billion in revenue during the quarter, up just 4% from the year-earlier period. That increase was driven by higher uptake of Keytruda for earlier-stage cancers and strong demand for the drug for metastatic cancers, which spread to other parts of the body. Still, sales came under the $7.43 billion that analysts had expected, according to StreetAccount estimates. Notably, Merck continued to see trouble with China sales of Gardasil, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S. In February, Merck announced a decision to halt shipments of Gardasil into China beginning that month and going through at least mid-2025. Investors will likely be looking for updates on that effort during the earnings call on Thursday. The Chinese market makes up the majority of the blockbuster shot's international revenue. Merck is hoping that Gardasil's expanded approval for men ages 9 to 26 in China will help boost uptake of the shot. Gardasil raked in $1.33 billion in sales, down 41% from the first quarter of 2024 primarily due to lower demand in China. That's below the $1.45 billion that analysts were expecting, according to StreetAccount estimates. China has retaliated with tariffs of 125% on goods from the U.S. Some experts said China's tariffs on U.S. products could lead to increased prices or limited supply of some popular Western medicines for Chinese patients, Reuters reported. Merck's animal health division, which develops vaccines and medicines for dogs, cats and cattle, posted nearly $1.59 billion in sales, up 5% from the same period a year ago. The company said higher demand for livestock products and sales from Elanco's aqua business, which it acquired last year, drove that growth.
